A team of physicists at the Institut Lumière Matière (CNRS/Université Claude Bernard Lyon 1), in collaboration with the Cancer Research Center of Lyon (CNRS/INSERM/ Université Claude Bernard Lyon 1/Centre Léon Bérard/Hospices civils de Lyon), has demonstrated the potential, for oncology, of an imaging technique based only on the physical properties of tumors. It can differentiate populations of malignant cells and monitor how effective an anticancer treatment is. These results, published in Physical Review Letters on January 8, 2019, should help in the design of new therapeutic molecules and in the personalization of treatments.
Despite a good understanding of the biology of cancer, 90% of experimental drugs fail during clinical trials. It is also increasingly suspected that the mechanical properties of tumors influence disease progression, and treatment efficacy. Although we can evaluate tumor elasticity globally, it is more difficult to measure local rigidity deep down and to see whether the core of the tumor resists the penetration of therapeutic liquids. To probe these physical properties, the researchers have used a noncontact imaging technique that does not require the use of contrast agents – therefore that does not disturb tissue function – that exploits natural infinitesimal vibrations of matter.
To recapitulate the behavior of colorectal tumors in vitro, the researchers created organoids, spheres with diameter 0.3 mm formed by the aggregation of tumor cells. They focused a red laser beam onto these objects. The infinitesimal vibrations of the sample, generated by thermal agitation, modify very slightly the color of the light beam that exits the sample. By analyzing this light, a map of the mechanical properties of the model tumors is created: the more rigid the area scanned by the laser, the faster the vibrations and, in a manner comparable to the Doppler effect (the mechanism that makes a siren sound increasingly shrill as it gets closer), the greater the color change.
From organoids composed of two cell lines with different malignancies, the researchers have shown that they could distinguish the two cell types from their mechanical properties. Such information is crucial because it may allow diagnosis from biopsy analysis to be refined and offer better assessment of tumor grade. Local variations in mechanical properties after a drug treatment have also been monitored using this technique: the center of the tumor remains rigid longer than the edge, demonstrating the treatment’s efficacy gradient. So local measurement of mechanical properties could confirm the total destruction of the tumor and help in choosing as low a treatment dose and duration as possible.
This approach allows exploring the impact of mechanical properties on the therapeutic response. It should lead to more predictive in vitro tumor models for testing new therapeutic molecules and for combined therapies, which act for example on tissue rigidity to accelerate the penetration of active molecules in the center of the tumor. It could also provide new indicators to guide clinicians in personalization of therapies.
Learn more: Physics can show us the inside of tumors
The Latest on: Personalized cancer treatment
via Google News
The Latest on: Personalized cancer treatment
- Cancer/Tumor Profiling: Worldwide Markets Through 2019-2024 - The Increasing Use of Biomarkers in Cancer Profiling Drives the Marketon July 4, 2019 at 5:45 am
DUBLIN, July 4, 2019 /PRNewswire/ -- The "Cancer/Tumor Profiling Market by ... The increasing demand for personalized medicine and the growing need for point-of-care diagnostics is expected ... […]
- Global Cancer/Tumor Profiling Market Projected to Reach $12.4 Billion by 2024 from $7.5 Billion in 2019, at a CAGR of 10.5% - ResearchAndMarkets.comon July 4, 2019 at 5:14 am
They also showcase an enormous potential for directing personalized cancer therapy and treatment monitoring. The clinical applications segment is expected to grow at the highest rate during the ... […]
- Global Cancer/Tumor Profiling Market to 2024 (...on July 4, 2019 at 4:01 am
13.2 Qiagen N.V. 13.3 Neogenomic Laboratories, Inc. 13.4 Sysmex Corporation 13.5 HTG Molecular Diagnostics, Inc. 13.6 Helomics Corporation 13.7 Genomic Health, Inc. 13.8 Caris Life Sciences 13.9 ... […]
- Researchers use artificial intelligence to predict molecular classification of colorectal canceron July 4, 2019 at 3:47 am
Image-based procedures could therefore potentially revolutionize personalized therapy in colorectal cancer. Yet in order to use the new ... in the individual and use this in the future to guide ... […]
- Personalized Medicine Market US Trends 2019 | Global Size, Industry Analysis, Share, Sales Revenue and Key Players by Forecaston July 3, 2019 at 6:58 am
Personalized medicine promises enormous potential in the treatment of cancer. Personalized medicine has entered the mainstream in the treatment of oncology diseases and is changing the way such ... […]
- Using machine learning models to better predict bladder cancer stageson July 3, 2019 at 1:01 am
Tsigelny, along with his work at UC San Diego, is the chief science officer and co-founder of CureMatch, which provides decision support for doctors in personalized cancer medicine. SDSC Director ... […]
- Belong.Life raises $14 million to expand its digital cancer support networkon July 1, 2019 at 1:18 pm
“We at Belong are focused on building the most robust, hyper-personalized ... app enables those with cancer and their loved ones to explore and better manage treatment. By offering a suite ... […]
- UCSF Opens Precision Medicine Building for Adult Cancer Patientson July 1, 2019 at 11:34 am
The UCSF Bakar Precision Cancer Medicine Building (PCMB) will use highly advanced treatments such as immunotherapy, molecular profiling of tumors, and genetic counseling to deliver personalized care ... […]
- Have Cancer, Must Travel: Patients Left In Lurch After Hospital Closeson July 1, 2019 at 6:00 am
“Dad couldn’t have better or more personalized care anywhere ... which was “pretty cramped,” Baker said. As cancer treatments improved, it grew so rapidly that Mercy executives moved ... […]
- Have Cancer, Must Travel: Patients Left In Lurch After Town's Hospital Closeson June 29, 2019 at 5:03 am
"Dad couldn't have better or more personalized care anywhere," said his son ... which was "pretty cramped," Baker said. As cancer treatments improved, it grew so rapidly that Mercy executives moved it ... […]
via Bing News